Results 221 to 230 of about 115,818 (290)
Risk of lymphoma among people with HIV in the United States, 2001-2019. [PDF]
Tao J +10 more
europepmc +1 more source
Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL [PDF]
Bartlett, Nancy L.
core +1 more source
ABSTRACT Since 2004, patients receiving imatinib with relapse in non‐marrow sites were given dasatinib to preserve control of leukemic marrow. Remissions in CNS and other organs began to be reported and are continuously observed to present. With resistance to one BCR::ABL1 tyrosine kinase inhibitor and sensitivity to a dual BCR::ABL1/SRC inhibitor ...
I. Cunningham +4 more
wiley +1 more source
Incidental Detection of Neoplastic B Cells in the Colon Following Resection in a Patient With Adenocarcinoma. [PDF]
Vattikonda A, Saleh H, Dryden I, Pang M.
europepmc +1 more source
Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies
ABSTRACT Infections remain a leading cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL), reflecting both intrinsic immune dysfunction and therapy‐related immunosuppression. The pathogenesis of immunodeficiency in CLL is multifactorial: neoplastic B cells impair humoral immunity, T cells are functionally exhausted, and ...
Enrica Antonia Martino +10 more
wiley +1 more source
A novel presentation of ocular chronic lymphocytic leukemia. [PDF]
Nakhleh LA +5 more
europepmc +1 more source
ABSTRACT Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used to treat malignant and non‐malignant diseases. Following allogeneic HSCT, patients are particularly vulnerable to vaccine‐preventable diseases (VPD) because conditioning depletes immune cells, including memory cells.
Hélène Buvelot +3 more
wiley +1 more source
Composite chronic lymphocytic leukemia and mantle cell lymphoma involving the bone marrow: a case report and literature review. [PDF]
Demianets R +9 more
europepmc +1 more source
ABSTRACT This retrospective study evaluates the efficacy and safety of donor lymphocyte infusion (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT) in children. We describe the long‐term use of preemptive, prophylactic, and therapeutic DLI with a gradual dose increase in half‐log increments.
Dinah Walther +7 more
wiley +1 more source

